Peak6 Investments LLC Bei Gene, Ltd. Transaction History

Peak6 Investments LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$129.52 - $174.32 $259,040 - $348,640	2,000 New	2,000 $285,000
Q2 2023 Aug 11, 2023	BUY	$178.3 - $266.78 $123,918 - $185,412	695 Added 228.62%	999 $178,000
Q1 2023 May 12, 2023	BUY	$215.53 - $274.5 $65,521 - $83,448	304 New	304 $65,000
Q2 2022 Aug 12, 2022	SELL	$121.11 - $216.05 $56,195 - $100,247	-464 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$146.52 - $269.56 $67,985 - $125,075	464 New	464 $88,000
Q4 2019 Feb 13, 2020	SELL	$115.78 - $208.34 $227,160 - $408,763	-1,962 Closed	0 $0
Q3 2019 Nov 08, 2019	BUY	$120.61 - $148.29 $30,876 - $37,962	256 Added 15.01%	1,962 $240,000
Q2 2019 Aug 14, 2019	SELL	$113.99 - $146.86 $136,104 - $175,350	-1,194 Reduced 41.17%	1,706 $211,000
Q4 2018 Feb 13, 2019	BUY	$107.01 - $175.15 $5,243 - $8,582	49 Added 1.72%	2,900 $407,000
Q3 2018 Nov 13, 2018	BUY	$152.62 - $189.66 $435,119 - $540,720	2,851 New	2,851 $491,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Peak6 Investments LLC with notifications on news.